Key facts
as of Sep 2026- Upstream Biotechnology’s last known valuation is $1.4M (Sep 2025).
- It has raised $830K across 1 recorded rounds; the latest was Seed Round ($625K) in Aug 2025.
- Notable investors include US National Science Foundation, SVG Ventures|THRIVE, Ag Ventures Alliance, AgLaunch, National Science Foundation Innovation Corps Program.
- 4 institutional filers report fund marks on Upstream Biotechnology across 39 filings.
- Upstream Biotechnology has filed 1 Form D with the SEC, most recently Sep 2025 ($625K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Upstream Biotechnology
Recorded secondary trades
No secondary trades in Upstream Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 39 fair-value marks on Upstream Biotechnology between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout Upstream Biotechnology
Developer of disease-resistant crops intended to eliminate pesticide use. The company uses patented technology to alter upstream DNA sequences to turn on a defensive gene while also using newly discovered sequence elements called upstream open reading frames, enabling farmers to control pesticide use, reduce production costs, increase crop yield and help meet the demands of this new agricultural landscape.
- Sector
- Materials and Resources
- HQ
- Durham, NC, United States
- Founded
- 2017
- Employees
- 7
- Website
- upstreambiotech.com/
- Ownership
- Privately Held (backing)